UC Davis Alzheimer's Disease Research Center

项目摘要/摘要--总体 加州大学戴维斯分校阿尔茨海默病研究中心(UCD ADRC)的使命是促进 创新和丰富的研究环境，专注于了解大脑老化的异质性 这最终将导致有效的治疗方法来预防或减轻痴呆症。 这种方法源于这样一个前提，即强调多样性会促进发现并有助于 翻译科学以及减少大脑健康和护理方面的差异。要做到这一点 作为使命，UCD ADRC开发了创新的方法和独特的研究设计，以招募和保留一名 具有高度人口统计学差异的临床和尸检队列。所有UCD ADRC参与者都是纵向的 通过广泛的临床、血液和成像生物标记物以及 发展最先进的定量神经病理学。UCD ADRC通过一个 强大的研究基础设施、最先进的数据库管理和高度协作的环境 包括七个整合良好的资源核心和一个研究教育部分(REC)，旨在 促进新的研究努力和干预措施、研究成果的传播、教育和培训 以及鼓励研究人员的发展。我们的方法解决了国家统计局设定的几个里程碑 阿尔茨海默氏症项目法案，到2025年有效治疗阿尔茨海默病及相关疾病(ADRD)。 这些措施包括但不限于：1)M1.L.，评估少数族裔和种族之间的差距 AD风险较高的人群以降低风险和改善认知结果，2)M2.H.，完全 确定混合病理的特征并确定独特的危险因素，3)M5-7，加速发展 预防、阻止或逆转阿尔茨海默病(AD)病程的治疗，4)M9，早期改善 通过发现新的成像和血液生物标记物进行诊断，5)M8，发展为新的痴呆症 预防战略，以及6)M13.E.，通过资助照顾者研究来支持照顾者。UCD ADRC还通过使用研究直接支持对不同社区的多种流行病学研究 方法和人员，以进一步了解痴呆症风险的降低、早期诊断和 关于衰老和痴呆的各种神经病理学。 我们的努力反映了日益老龄化和多样化的美国人口不断变化的需求，这是 预计到本世纪中叶将增加到近1400万人。此外，虽然阿尔茨海默病仍然是主要的病理 痴呆症的病因，最近的研究--包括UCD ADRC的一项--发现痴呆症的病理是 多因素和高度异质性，部分原因是AD和血管疾病并存，这 因耳鼻特征而异，强调为痴呆症预测的一部分，并且可以修改 即使在晚年也要接受治疗。UCD ADRC是唯一有资格支持这一研究重点的机构 对未来ADRD的诊断和治疗有相当大的影响。

PROJECT SUMMARY/ABSTRACT - Overall The mission of the UC Davis Alzheimer’s Disease Research Center (UCD ADRC) is to promote a highly innovative and enriched research environment focused on understanding the heterogeneity of brain aging among diverse populations that will ultimately lead to effective therapies to prevent or mitigate dementia. This approach stems from the premise that emphasizing diversity enhances discovery and contributes to translational science as well as reducing disparities in brain health and care. To accomplish this mission, the UCD ADRC has developed innovative methods and a unique study design to recruit and retain a highly demographically diverse clinical and autopsy cohort. All UCD ADRC participants are longitudinally followed and deeply phenotyped with extensive clinical, blood and imaging biomarker measures as well as developing state-of-the-art quantitative neuropathology. The UCD ADRC succeeds at these efforts through a robust research infrastructure, state-of-the-art database management and a highly collaborative environment consisting of seven well integrated resource cores and one research education component (REC) designed to facilitate new research efforts and interventions, dissemination of research findings, education and training as well as encouraging researcher development. Our approach addresses several milestones set by the National Alzheimer’s Project Act to effectively treat Alzheimer’s disease and associated disorders (ADRD) by 2025. These include, but are not limited to: 1) M1.L., evaluating disparities among ethnic and racial minority populations that are at higher risk for AD to mitigate risk and improve cognitive outcomes, 2) M2.H., fully characterizing mixed pathologies and identifying unique risk factors,3) M5-7., accelerating the development of treatments that would prevent, halt, or reverse the course of Alzheimer’s disease (AD), 4) M9., improving early diagnosis through discovery of novel imaging and blood biomarkers, 5) M8., developing novel dementia prevention strategies, and 6) M13.E.,supporting caregiving through funded caregiver research. The UCD ADRC also directly supports multiple epidemiological studies of diverse communities through use of research methods and personnel to gain further insights into dementia risk reduction, early diagnosis, and the impact of various neuropathologies on aging and dementia. Our efforts reflect the evolving needs of an increasingly older and more diverse US population, which is expected to rise to nearly 14 million by midcentury. Moreover, while AD continues to be the major pathological cause of dementia, more recent studies—including one from the UCD ADRC—find that dementia pathology is multifactorial and highly heterogeneous, due in part to the co-occurrence of AD and vascular disease, which varies by ethnoracial characteristics, is emphasized as part of dementia prediction and which can be modified by treatment even in later life. The UCD ADRC is uniquely qualified to support this research focus with a considerable impact on future ADRD diagnosis and treatment.